Proleukin (aldesleukin): Reviews and patient testimonials
Back to the list of medications
Medication indications
Proleukin
Treatment of metastatic renal cell carcinoma.
Risk factors associated with decreased response rates and median survival are:
- A performance status of ECOG*) 1 or greater
- More than one organ with metastatic disease sites
- A period of < 24 months between initial diagnosis of primary tumour and the date the patient is evaluated for Proleukin treatment.
*) ECOG (Eastern Cooperative Oncology Group) performance status: 0 = normal activity, 1 = symptoms but ambulatory; 2 = in bed less than 50% of time; 3 = in bed more than 50% of time, limited self-care; 4 = completely disabled, no self-care.
Response rates and median survival decrease with the number of risk factors present. Patients positive for all three risk factors should not be treated with Proleukin.
Molecule: aldesleukin
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.